. "Appendix D-10: The Prospects for Immunizing Against Plasmodium spp.." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
Although various observations suggest that vaccination against malaria may be possible, a number of factors suggest that development of a vaccine conferring effective long-lasting immunity against all or most strains and species will be difficult. Recrudesent infections may last as long as 2 years for P. falciparum to 30 years for P. malariae. Natural immunity builds slowly, and sterile immunity is rarely achieved (Miller, 1985; Perrin et al., 1984).
It may be possible, however, to raise the level of immunity (e.g., to sporozoite antigens) to a greater extent by vaccination since natural exposure to sporozoite before sequestration of the parasite in the liver is brief. In the case of antigenic fragments (e.g., from sporozoites), it may be possible to develop vaccines conferring long-lasting immunity by coupling fragments to carriers (e.g., toxoids), or by incorporating fragments into immunogenic bacterial fusion proteins. That protracted exposure to the natural disease is required for the development of immunity suggests that the parasite has evolved mechanisms for evading the human immune response. This may be particularly problematic in selecting merozoite antigens as candidate immunogens. Knowledge of parasite immune variation is incomplete, as is knowledge of the roles of humoral and cell-mediated responses in combatting the disease. These and other potential problems are discussed more fully by Ravetch et al. (1985).
Bruce-Chwatt, L.J. In press. Malaria and selective primary health care. Rev. Infect. Dis.
Chulay, J.D., M.Aikawa, C.Diggs, and J.D.Haynes. 1981. Inhibitory effects of immune monkey serum on synchronized Plasmodium falciparum cultures. Am. J. Trop. Med. Hyg. 30:12–19.
Cohen, S., I.A.McGregor, and S.Carrington. 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192:733–737.
Dame, J.B., J.L.Williams, T.F.McCutchan, J.L.Weber, R.A.Wirtz, W.T.Hockmeyer, W.L.Maloy, J.D.Haynes, I.Schneider, D.Roberts, G.S.Sanders, E.P.Reddy, C.L.Diggs, and L.H.Miller. 1984. Structure of the gene in encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225:593–599.
Gilles, H.M. 1981. Malaria. Brit. Med. J. 283:1382–1385.
Lancet. 1975. Epitaph for global malaria eradication. Lancet II: 662.
Miller, L.H. 1985. Research toward a malaria vaccine: A critical review. Pp. 1–11 in Vaccines 85. Molecular and Chemical Basis of Resistance to Parasitic, Bacterial, and Viral Diseases, R.A. Lerner, R.M.Chanock, and F.Brown, eds. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratories.
Miller, L.H., P.H.David, and T.J.Hadley. 1984. Perspectives for malaria vaccination. Phil. Roy. Royal Soc. London 307:99–108.